Cargando…
CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of vari...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787262/ https://www.ncbi.nlm.nih.gov/pubmed/35087829 http://dx.doi.org/10.3389/fcell.2021.770811 |
_version_ | 1784639322689896448 |
---|---|
author | Yi, Yonglin Qiu, Zhengang Yao, Zifu Lin, Anqi Qin, Yimin Sha, Ruizhan Wei, Ting Wang, Yanru Cheng, Quan Zhang, Jian Luo, Peng Shen, Weitao |
author_facet | Yi, Yonglin Qiu, Zhengang Yao, Zifu Lin, Anqi Qin, Yimin Sha, Ruizhan Wei, Ting Wang, Yanru Cheng, Quan Zhang, Jian Luo, Peng Shen, Weitao |
author_sort | Yi, Yonglin |
collection | PubMed |
description | Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC. |
format | Online Article Text |
id | pubmed-8787262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87872622022-01-26 CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy Yi, Yonglin Qiu, Zhengang Yao, Zifu Lin, Anqi Qin, Yimin Sha, Ruizhan Wei, Ting Wang, Yanru Cheng, Quan Zhang, Jian Luo, Peng Shen, Weitao Front Cell Dev Biol Cell and Developmental Biology Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC. Frontiers Media S.A. 2022-01-11 /pmc/articles/PMC8787262/ /pubmed/35087829 http://dx.doi.org/10.3389/fcell.2021.770811 Text en Copyright © 2022 Yi, Qiu, Yao, Lin, Qin, Sha, Wei, Wang, Cheng, Zhang, Luo and Shen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Yi, Yonglin Qiu, Zhengang Yao, Zifu Lin, Anqi Qin, Yimin Sha, Ruizhan Wei, Ting Wang, Yanru Cheng, Quan Zhang, Jian Luo, Peng Shen, Weitao CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title | CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_full | CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_fullStr | CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_full_unstemmed | CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_short | CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_sort | camsap1 mutation correlates with improved prognosis in small cell lung cancer patients treated with platinum-based chemotherapy |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787262/ https://www.ncbi.nlm.nih.gov/pubmed/35087829 http://dx.doi.org/10.3389/fcell.2021.770811 |
work_keys_str_mv | AT yiyonglin camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT qiuzhengang camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT yaozifu camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT linanqi camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT qinyimin camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT sharuizhan camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT weiting camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT wangyanru camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT chengquan camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT zhangjian camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT luopeng camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT shenweitao camsap1mutationcorrelateswithimprovedprognosisinsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy |